Drug intelligence / Profile preview

codeine phosphate + pseudoephedrine hydrochloride + triprolidine

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

Codeine phosphate + pseudoephedrine hydrochloride + triprolidine is an oral small-molecule combination cough and cold product used for the temporary relief of cough and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. The combination contains **codeine phosphate**, an opioid antitussive that suppresses coughing primarily through central agonism at opioid receptors in the medullary cough center; **pseudoephedrine hydrochloride**, an indirect sympathomimetic decongestant that promotes norepinephrine release and reduces nasal congestion through adrenergic vasoconstrictive effects; and **triprolidine**, a first-generation H1 antihistamine that counters histamine-mediated allergic symptoms. It has been marketed under brand names including **Triacin-C** and **Pseudodine C**, typically as an oral syrup formulation.

Brand names
Triacin-CPseudodine C
Other names
codeine phosphate + pseudoephedrine hydrochloride + triprolidine hydrochloride
02

Targets

ADRB1 (β1)MOR (Mu opioid receptor)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on codeine phosphate + pseudoephedrine hydrochloride + triprolidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on codeine phosphate + pseudoephedrine hydrochloride + triprolidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call